Avastin (bevacizumab) - 400mg - For Intravenous Use | National Museum of American History

There are restrictions for re-using this image. For more information, visit the Smithsonian's Terms of Use page .

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more.

View manifest View in Mirador Viewer

Avastin; front

Avastin; back

Avastin; side

Avastin; interior

Avastin; box and bottle

Avastin; bottle

Description (Brief):

(From box) For Intravenous Use

Description (Brief)

(From insert)

Description (Brief)

Metastatic Colorectal Cancer (mCRC) Avastin is indicated for the first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-flurouracil-based chemotherapy.

Description (Brief)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Avastin is indicated for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel.

Description (Brief)

Glioblastoma Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate. There are no data demonstrating an improvement in disease-related symptoms or increased survival with Avastin.

Description (Brief)

Metastatic Renal Cell Carcinoma (mRCC) Avastin is indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa.

Date Made: ca 2013Product Expiration Date: 2014-10

Maker: Genentech, Inc.

Location: Currently not on view

Place Made: United States: California, South San Francisco

See more items in: Medicine and Science: Medicine, Health & Medicine, The Antibody Initiative, Antibody Initiative: Monoclonal Antibodies

Exhibition:

Exhibition Location:

Credit Line: Gift of Genentech, Inc.

Data Source: National Museum of American History

Id Number: 2013.0069.02Catalog Number: 2013.0069.02Accession Number: 2013.0069Maker Number: 510569

Object Name: pharmaceuticalbiological

Physical Description: metal (overall material)plastic (overall material)glass (overall material)cardboard (overall material)bevacizumab, 400 mg (20mg/mL) (overall ingredient)Measurements: overall: 1 1/2 in x 2 3/4 in x 5 1/4 in; 3.81 cm x 6.985 cm x 13.335 cmavastin bottle: 2 1/2 in x 1 1/4 in; 6.35 cm x 3.175 cmoverall: 5 1/4 in x 2 3/4 in x 1 1/2 in; 13.335 cm x 6.985 cm x 3.81 cm

Metadata Usage: CC0

Guid: http://n2t.net/ark:/65665/ng49ca746ad-d911-704b-e053-15f76fa0b4fa

Record Id: nmah_1445117

Our collection database is a work in progress. We may update this record based on further research and review. Learn more about our approach to sharing our collection online.

If you would like to know how you can use content on this page, see the Smithsonian's Terms of Use. If you need to request an image for publication or other use, please visit Rights and Reproductions.